Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,713 total articles
Similarweb is trading at $7.63 with a market cap of roughly $668M after a mixed earnings cadence and conservative FY26 guide. The stock is discounting execution risk, but enterprise adoption and AI-enabled competitive intelligence tailwinds are laying the groundwork for a mid-term re-rate. This is a tactical long idea sized for swing traders who ca…
Advanced Micro Devices recently cleared a milestone and the chart. With a $1.03T market cap, a stretched multiple, and accelerating AI wins, AMD is a high-conviction long trade for long-term traders who can stomach valuation risk. Enter at $631.00, stop at $580.00, target $1,000.00 over 180 trading days, with clearly defined catalysts and risk cont…
Topaz Energy trades at a yield-friendly premium backed by operator-funded reserve renewals that preserve royalty cash flow. The technical setup is oversold and average volume has been robust, presenting a defined-entry trade for investors comfortable with energy cyclicality.
Intuit is trading well below prior highs after a dramatic derating. The company still generates healthy free cash flow ($8.66B FY2026), 24% ROE and double-digit growth from its 'Big Bets', making the current ~$73.7B market cap look compelling around $276. This is a tactical long trade for patient investors who can tolerate execution risk from AI di…
Energy Transfer (ET) looks oversold today at $20.22 with RSI in the low 30s and heavy volume. The company generates meaningful free cash flow ($5.22B), trades at an EV/EBITDA of ~8x and yields roughly 6.6%. Combine that with a $5.9B project backlog tied to AI data-center gas demand and you’ve got a high-probability, mid-term trade: enter on the dip…
Q32 Bio (QTTB) is a small-cap biotech with programs targeting immune drivers of alopecia areata and other immune-mediated diseases. A May 2026 private placement and a prior asset sale have reduced near-term cash risk, while the stock is trading near oversold technical levels and a sub-$200M enterprise value. We recommend a mid-term long trade that …
NFLX has corrected into the mid-$60s and low-$70s after a broad sentiment shift in September. With a market cap near $296B, double-digit revenue growth, and $11.15B in free cash flow, the risk/reward favors a mid-term long trade from $71.15 with a disciplined stop at $64 and a target near $85 over ~45 trading days.
Kratos is executing a fast ramp in manufacturing capacity for unmanned systems, turbojets and hypersonic-related hardware. Revenue and EPS are accelerating (Q2 revenue +30.5% YoY; Q2 adjusted EPS $0.21) and the company raised guidance to $1.75-$1.81B for the year. The shares trade at lofty multiples, but technical indicators, short interest dynamic…
Ping An (PNGAY) trades at a rock-bottom P/B of 0.33 and P/E of 5.35 with a 4.9% dividend yield and recent profit momentum. I recommend a mid-term (45 trading days) long trade: entry $13.55, target $16.50, stop $12.80. The trade banks on cheap valuation, improving profitability and convertible-bond liquidity, while watching for macro and regulatory …
IBM fell from its 2026 high and spent the summer digesting gains. With a $212B market cap, 20x earnings, $13.8B in free cash flow and a dividend yield near 3%, the stock looks de-risked for a swing trade that leans on an earnings/corporate spending normalization and renewed investor focus on AI and quantum initiatives.
Oracle's force majeure notice on Project Jupiter is headline-heavy but not existential. The company still trades at ~22x earnings with an EV/EBITDA near 14.2 and a $414B market cap. We recommend a long position entered on weakness: entry $135.00, stop $122.00, target $170.00 over a position-horizon trade (46-180 trading days). Catalysts include pro…
electroCore is growing top line (Q1 2026 sales $9.6M, Q2 $9.5M) while trimming losses and guiding to >30% revenue growth for 2026. With a market cap near $100M and EV/sales roughly 2.7x, the stock offers an asymmetric risk/reward if management continues to convert revenue growth into operating leverage. I outline an actionable long: entry $11.22, s…
Alkermes' acquisition of Avadel gives it Lumryz, a sleep disorder product with upside in idiopathic hypersomnia (IH). With free cash flow of $221.7M and a market cap of ~$6.85B, the company can invest behind commercialization. Technicals are oversold and short interest remains elevated, creating a setup for a tactical long. This trade idea lays out…
InnovAge (INNV) runs PACE centers for high-cost, dual-eligible seniors. Recent enrollment gains, improving margins and a positive free cash flow profile argue for better care economics ahead. Technicals show an oversold bounce and a secondary offering is already priced into the market. I recommend a long trade sized for a medium-risk portfolio with…
Fiserv trades near its 52-week low with a market cap of about $24.7B, free cash flow of roughly $3.9B and attractive valuation multiples (P/E ~8.8, EV/EBITDA ~6.7). Management turnover and a weak growth profile have crushed the multiple, but activist involvement, debt refinancing and operational levers give a plausible path to margin and multiple r…
Nutex Health has swung from a beaten-down story earlier this year to a company trading near its 52-week high. The fundamentals - double-digit ROE, robust free cash flow, and reasonable valuation multiples - support a tactical long for patient speculators. That thesis rests on resolution or containment of several legal and arbitration exposures; if …
TransMedics is trading at a multi-month low relative to its 52-week range while still showing double-digit revenue growth and improved guidance. With a market cap near $3.0B, ample liquidity metrics, and a growing service stream, the risk/reward favors a long entry around current levels. Maintain a strict stop and monitor legal and margin execution…
Entravision is trading near $7.41 after a volatile run from a $1.95 low to a $13.74 52-week peak. The company has real digital-ad growth and delivered Q2 revenue of $100.7M (+22% y/y). At a $684M market cap with free cash flow of $54.3M and EV/EBITDA ~8.0, the valuation looks attractive versus the company’s recent growth profile. That said, debt-to…
Capital Tankers looks like a compact, under-owned tanker name that could rerate if charter rates and consolidation dynamics that helped Okeanis carry higher multiples show up across the sector. This is a tactical buy with defined risk: entry at $1.20, stop at $0.95, and a primary target at $2.10 over a mid-term 45 trading day horizon.
Rocket Companies (RKT) trades near its 52-week low with a market cap roughly $34B, weak recent technicals, but fundamentals and activist buying argue for a contrarian entry. I outline an actionable mid-term trade with entry, stop and target and explain the catalysts that could push the stock higher over the next 45 trading days.
M/I Homes (MHO) trades at a modest multiple, generates meaningful free cash flow and carries low leverage relative to peers. With shares around $138.75 and a market cap near $3.5B, the combination of cash generation, a reasonable P/E of ~11, and a manageable debt load makes MHO a practical mid-term trade on dips ahead of housing catalysts and the O…
GitLab (GTLB) looks positioned to capture disproportionate share of AI-driven software development spend. With new ARR growth re-accelerating to ~42% and Q2 revenue of $286.25M (+21% YoY) driven by SaaS strength, the stock offers a manageable risk/reward from current levels. This idea lays out a long trade with entry, stop, and target tailored to a…
Pfizer looks attractively positioned for a 46-180 trading day trade. The core business continues to generate strong cash flow, management has prioritized capital return, and several pipeline and commercial catalysts should re-rate the stock. Enter at $35.00, with a stop at $30.00 and a target of $50.00.
Taiwan Semiconductor Manufacturing Co. (TSM) is trading near $451 with a $2.34T market cap, healthy technical momentum, and direct exposure to secular AI and smartphone upgrades. The company's scale, 72.5% foundry share reported in recent coverage, and the upcoming A14 node roadmap justify a long position. This trade idea lays out entry, stop and t…
SpaceX's tighter integration with Grok-style AI tools creates a realistic pathway to higher launch cadence, lower ops cost and better Starlink monetization. We upgrade our stance to a constructive rating and lay out an actionable long trade with entry, target and stop-loss paired to a 180-trading-day horizon.
